BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 10492237)

  • 1. The chimpanzee as a model of human benign prostatic hyperplasia.
    Steiner MS; Couch RC; Raghow S; Stauffer D
    J Urol; 1999 Oct; 162(4):1454-61. PubMed ID: 10492237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
    J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men.
    Liu CC; Huang SP; Li WM; Wang CJ; Chou YH; Li CC; Huang CH; Wu WJ
    Urology; 2007 Oct; 70(4):677-80. PubMed ID: 17991536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Experimental research on spontaneous benign prostatic hyperplasia in old dogs].
    Cai RF; Cui YG; Hua LX; Jia Y; Ma DZ; Wang XH
    Zhonghua Nan Ke Xue; 2003 Dec; 9(9):651-3, 657. PubMed ID: 14727348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and experimental studies of benign prostatic hyperplasia.
    Coffey DS; Walsh PC
    Urol Clin North Am; 1990 Aug; 17(3):461-75. PubMed ID: 1695775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997.
    Sarma AV; Jacobson DJ; McGree ME; Roberts RO; Lieber MM; Jacobsen SJ
    J Urol; 2005 Jun; 173(6):2048-53. PubMed ID: 15879823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia.
    Roehrborn CG
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S19-26. PubMed ID: 19002120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional and anatomical effects of hormonally induced experimental prostate growth: a urodynamic model of benign prostatic hyperplasia (BPH) in the beagle.
    Yokota T; Honda K; Tsuruya Y; Nomiya M; Yamaguchi O; Gotanda K; Constantinou CE
    Prostate; 2004 Feb; 58(2):156-63. PubMed ID: 14716740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
    Ramos CG; Carvahal GF; Mager DE; Haberer B; Catalona WJ
    J Urol; 1999 Nov; 162(5):1587-90. PubMed ID: 10524873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benign prostatic hyperplasia: a review of its histogenesis and natural history.
    Oesterling JE
    Prostate Suppl; 1996; 6():67-73. PubMed ID: 8630233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
    Chung BH; Hong SJ; Cho JS; Seong DH
    BJU Int; 2006 Apr; 97(4):742-6. PubMed ID: 16536765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of benign prostatic hyperplasia disease.
    Marks LS; Roehrborn CG; Andriole GL
    J Urol; 2006 Oct; 176(4 Pt 1):1299-306. PubMed ID: 16952616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of prostate-specific antigen and prostate volume in Korean men with biopsy-proven benign prostatic hyperplasia.
    Lee SE; Chung JS; Han BK; Moon KH; Hwang SI; Lee HJ; Choe G; Hong SK
    Urology; 2008 Mar; 71(3):395-8. PubMed ID: 18342171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathology of benign prostatic hyperplasia.
    Roehrborn CG
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S11-8. PubMed ID: 19002119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Definition of at-risk patients: baseline variables.
    Roehrborn CG
    BJU Int; 2006 Apr; 97 Suppl 2():7-11; discussion 21-2. PubMed ID: 16507046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New histopathological experimental model for benign prostatic hyperplasia: stromal hyperplasia in rats.
    Mori F; Oda N; Sakuragi M; Sakakibara F; Kiniwa M; Miyoshi K
    J Urol; 2009 Feb; 181(2):890-8. PubMed ID: 19095262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 May; 47(3):149-63. PubMed ID: 11351344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Correlation of benign prostatic hyperplasia with hyperlipemia].
    Li PJ; Zhang XH; Guo LJ; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):387-9. PubMed ID: 15854349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.